Greenwich LifeSciences, Inc. insiders have been one-way buyers this past year: one person put roughly $586,000 into the stock and nobody sold on the open market.
Patel Snehal (CEO) made the biggest buy, worth around $92,000. Notably, at least one C-suite executive was among the buyers.
Big money check: 58 institutions held GLSI as of Q2 2026, and more funds bought than sold. Last full quarter: net buying by insiders. Insiders bought in 5 of the last 7 full quarters.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Jul 30, 2026 | Patel Snehal | CEO | Buy | 700 | $13.10 | $9K | SEC |
| Jul 30, 2026 | Patel Snehal | CEO | Buy | 1,500 | $13.59 | $20K | SEC |
| Jul 29, 2026 | Patel Snehal | CEO | Buy | 1,500 | $13.62 | $20K | SEC |
| Jul 27, 2026 | Patel Snehal | CEO | Buy | 1,100 | $12.88 | $14K | SEC |
| Jul 27, 2026 | Patel Snehal | CEO | Buy | 2,500 | $13.14 | $33K | SEC |
| Jan 15, 2026 | Patel Snehal | CEO | Buy | 1,800 | $29.83 | $54K | SEC |
| Jan 14, 2026 | Patel Snehal | CEO | Buy | 2,900 | $27.54 | $80K | SEC |
| Jan 5, 2026 | Patel Snehal | CEO | Buy | 4,300 | $21.36 | $92K | SEC |
| Jan 2, 2026 | Patel Snehal | CEO | Buy | 2,900 | $21.73 | $63K | SEC |
| Dec 19, 2025 | Patel Snehal | CEO | Buy | 4,100 | $12.62 | $52K | SEC |
| Nov 28, 2025 | Patel Snehal | CEO | Buy | 4,600 | $8.37 | $39K | SEC |
| Nov 12, 2025 | Patel Snehal | CEO | Buy | 10,600 | $8.43 | $89K | SEC |
| Nov 4, 2025 | Patel Snehal | CEO | Buy | 2,300 | $9.26 | $21K | SEC |
| Apr 29, 2025 | Patel Snehal | CEO | Buy | 3,600 | $9.88 | $36K | SEC |
| Apr 22, 2025 | Patel Snehal | CEO | Buy | 5,400 | $8.98 | $48K | SEC |
In the last 12 months Greenwich LifeSciences, Inc. insiders made open-market purchases worth about $586,000 and sales worth about $0. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in GLSI was filed on 2026-07-30.
58 investment managers reported holding GLSI in SEC Form 13F filings for Q2 2026.
No congressional trades in GLSI were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).